TScan Therapeutics Updates Board of Directors

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in T cell receptor (TCR)-engineered T cell therapies for cancer treatment, has announced significant changes to its Board of Directors. Garry A. Nicholson, an established executive with over 35 years of experience in oncology development and commercialization, has been appointed to the board. Concurrently, Timothy Barberich has retired from his positions as a Member and Chair of the Board, and Stephen Biggar, M.D., Ph.D., will take over as Chair.

Nicholson's extensive background includes serving as the president of Pfizer Oncology, where he managed the global oncology franchise. Nicholson has also held leadership roles at Eli Lilly and Company and was the president and CEO of XTuit Pharmaceuticals. He currently chairs the boards of G1 Therapeutics, Day One Biopharmaceuticals, and Abdera Therapeutics, and has previously served on the boards of Turning Point Therapeutics, Five Prime Therapeutics, Tmunity, and TESARO.

CEO Gavin MacBeath, Ph.D., expressed enthusiasm about Nicholson's appointment, citing his regulatory and commercial expertise as invaluable for advancing TScan's clinical programs. Nicholson himself voiced eagerness to contribute to TScan's mission to deliver life-changing therapies to cancer patients.

Timothy Barberich, who has been with TScan since 2019 and served as Chair since 2021, has retired. MacBeath acknowledged Barberich's contributions to the company, which has grown from a discovery-stage organization to a clinical-stage entity under his guidance. Stephen Biggar, who has been part of the board since 2021, will now assume the role of Chair.

TScan Therapeutics is focused on developing TCR-engineered T cell therapies for cancer patients. Their lead candidates, TSC-100 and TSC-101, are in development to prevent relapse in patients with hematologic malignancies who have undergone allogeneic hematopoietic cell transplantation. The company is also working on TCR-T therapies for various solid tumors. To support these efforts, TScan has established an ImmunoBank, a repository of therapeutic TCRs that can be customized for different cancers.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!